Purvalanol A

Key Product Details

Product Description

Purvalanol A is a cyclin-dependent kinase (cdk) inhibitor (reported IC₅₀ values are 4, 4 - 70, 75 - 240 and 100 nM for cdk1, cdk2, cdk5 and cdk 7, respectively). Reversibly arrests synchronised cells in G1 and G2, and inhibits cell proliferation and cell death.

Licensing Information

Sold under license from the Regents of the University of California

Product Specifications for Purvalanol A

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Purvalanol A

The following data is based on the product molecular weight 388.90.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

3 2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.57 mL	12.86 mL	25.71 mL
5 mM	0.51 mL	2.57 mL	5.14 mL
10 mM	0.26 mL	1.29 mL	2.57 mL
50 mM	0.05 mL	0.26 mL	0.51 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 29 publications citing the usage of this product.

• Jorda How selective are pharmacological inhibitors of cell-cycle-regulating cyclin-dependent kinases? J.Med.Chem. 2018 PMID: 30234987
• Villerbu Cellular effects of purvalanol A: a specific inhibitor of cyclin-dependent kinase activities. Int.J.Cancer 2002 PMID: 11857351
• Gray Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 1998 PMID: 9677190
• Gray ATP-site directed inhibitors of cyclin-dependent kinases. Curr.Med.Chem. 1999 PMID: 10495356
• Bain The specificities of protein kinase inhibitors: an update. Biochem.J. 2003 PMID: 12534346

Product Documents for Purvalanol A